Company Overview
Company Type: Public Company
Website: www.intellipharmaceutics.com
Number of Employees: 11
Ticker: IPCI (TSX)
Year Founded: 1998


Business Description
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
1.2
Market Capitalization
2.8
TEV/Total Revenue
4.8x
EBITDA
(1.3)
Total Enterprise Value
5.6
TEV/EBITDA
NM
EBIT
(1.6)
Cash & ST Invst.
0.2
P/Diluted EPS Before Extra
NM
Net Income
(2.2)
Total Debt
3.1
Price/Tang BV
NM
Total Assets
2.4
Total Debt/EBITDA
NM


Currency in CAD in mm, LTM as of May-31-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023

Key Professionals
Name
Title
Odidi, Isa 
Co-Founder, Chairman of the Board, CEO & Co-Chief Scientific Officer
Odidi, Amina 
President, COO, Co-Chief Scientific Officer, Acting CFO & Executive Director
Shaideen, Fazayill 
Controller
Yat, Patrick N.
Vice-President of Chemistry & Analytical Services

Key Board Members
Name
Title
Odidi, Isa 
Co-Founder, Chairman of the Board, CEO & Co-Chief Scientific Officer
Odidi, Amina 
President, COO, Co-Chief Scientific Officer, Acting CFO & Executive Director
Betts, Norman M.
Independent Non-Executive Director
Graham, Shawn 
Independent Non-Executive Director
Madhani, Bahadur 
Independent Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
30 Worcester Road | Toronto, ON | M9W 5X2 | Canada
Phone: 416 798 3001    Fax: 416 798 3007

Current and Pending Investors
Anson Funds Management LP, Armistice Capital LLC, Par Pharmaceutical Companies Inc., Sabby Management, LLC, Tekla Capital Management LLC

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.09
Market Cap (mm)
2.8
Open
 0.09
Shares Out. (mm)
33.1
Previous Close
 0.09
Float %
87.1%
Change on Day
0.00
Shares Sold Short (mm)
0.0
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.09/ 0.09
Diluted EPS Excl. Extra Items
(0.07)
52 wk High/Low
 0.14/ 0.04
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0020
Avg 3M Dly Vlm (mm)
0.0092
Beta 5Y
0.68


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
TSX:IPCI - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Vasogen Inc.
As of October 22, 2009, Vasogen Inc. was acquired by IntelliPharmaCeutics Ltd., in a reverse merger transaction. Vasogen Inc. focuses on the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neuro-inflammatory disorders. It is not advancing the development of its products and is focused is on exploring strategic options that may include a sale of the company, a merger, an acquisition, or other strategic alternative. The company was founded 1980 and is headquartered in Mississauga, Canada.

United States and Canada
Biotechnology
-
4.00
0.00
Ready Capital Corp
As of September 10, 2004, Ready Capital Corp was acquired by IntelliPharmaCeutics Ltd. Ready Capital Corp is a blank check company.

United States and Canada
Asset Management and Custody Banks
-
-
0.00
Vasogen Ireland Limited
Vasogen Ireland Limited owns the technology and intellectual property rights related to the immune modulation therapies. The company was incorporated in 1998 and is based in Dublin, Ireland. Vasogen Ireland is a subsidiary of IntelliPharmaCeutics International Inc.

Europe
Health Care Services
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-22-2021
Apr-22-2021
Private Placement
Target
Intellipharmaceutics International Inc. (TSX:IPCI)


3.09
Nov-15-2019
Nov-15-2019
Private Placement
Target
Intellipharmaceutics International Inc. (TSX:IPCI)


0.25
Aug-26-2019
Aug-26-2019
Private Placement
Target
Intellipharmaceutics International Inc. (TSX:IPCI)


0.14
Jul-08-2019
-
Private Placement
Target
Intellipharmaceutics International Inc. (TSX:IPCI)


10.00
May-01-2019
May-01-2019
Private Placement
Target
Intellipharmaceutics International Inc. (TSX:IPCI)


1.05
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-14-2023
Annual General Meeting
Intellipharmaceutics International Inc., Annual General Meeting, Sep 14, 2023
Jun-05-2023
Auditor Going Concern Doubts
Intellipharmaceutics International Inc. Auditor Raises 'Going Concern' Doubt
May-27-2022
Annual General Meeting
Intellipharmaceutics International Inc., Annual General Meeting, May 27, 2022
Feb-28-2022
Auditor Going Concern Doubts
Intellipharmaceutics International Inc. Auditor Raises 'Going Concern' Doubt
Jan-13-2022
Executive/Board Changes - Other
Intellipharmaceutics International Inc. Announces Kenneth Keirstead, A Member of Board of Directors, Passed Away

Competitors
Amgen Inc. (NasdaqGS:AMGN), Bristol-Myers Squibb Company (NYSE:BMY), Eisai Co., Ltd. (TSE:4523), Genentech, Inc., I-Flow, LLC, Merck & Co., Inc. (NYSE:MRK), Novartis AG (SWX:NOVN), Sanofi (ENXTPA:SAN), Takeda Pharmaceutical Company Limited (TSE:4502)

M&A Advisors
Gowling WLG International Limited


Advisors
Most Recent Auditor
MNP LLP
M&A Advisors
Gowling WLG International Limited
Private Placement Advisors
Ladenburg Thalmann & Co. Inc., Loewen Ondaatje McCutcheon Limited, Investment Banking Arm
Public Offering Advisors
Buchanan Ingersoll & Rooney PC, Deloitte & Touche LLP (Canada), Deloitte LLP, Gowling WLG (Canada) LLP, Gowling WLG International Limited, H.C. Wainwright & Co., LLC, MNP LLP


Most Recent Auditor
Meyers Norris Penny LLP - MNP LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Oct 06, 2023 01:32 AM
IPCI
Intellipharmaceutics International Inc (IPCI.TSE) - Financial and Strategic SWOT Analysis Review
Reports
125
S&P Global Compustat

Oct 05, 2023 03:43 AM
IPCI
Intellipharmaceutics International Inc 2023_10_05
Reports
14
ValuEngine, Inc.

Oct 02, 2023 06:19 AM
IPCI
ValuEngine - Toronto Quantitative Stock Report for IPCI
Reports
5
MarketLine

Sep 30, 2023 06:01 AM
IPCI
IntelliPharmaCeutics International Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
31
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Sep 20, 2023 06:00 PM
IPCI
Rating Update for Intellipharmaceutics International Inc
EPS Estimates*
3
GlobalData

Sep 20, 2023 05:03 AM
IPCI
Intellipharmaceutics International Inc (IPCI.TSE) - Financial and Strategic SWOT Analysis Review
Reports
126
GlobalData

Sep 15, 2023 09:48 AM
IPCI
Intellipharmaceutics International Inc (IPCI.TSE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
53
S&P Global Compustat

Sep 07, 2023 03:29 AM
IPCI
Intellipharmaceutics International Inc 2023_09_07
Reports
14
GlobalData

Aug 18, 2023 04:45 AM
IPCI
Intellipharmaceutics International Inc (IPCI.NASD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
46
S&P Global Compustat

Jul 06, 2023 03:02 AM
IPCI
Intellipharmaceutics International Inc 2023_07_06
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Armistice Capital LLC

3,672,877

11.10

0.3

Dec-31-2022


Sabby Management, LLC

1,101,571

3.33

0.1

Mar-31-2022


Odidi Holdings Inc.

578,131

1.75

0.0

Jun-13-2023


Yat Ph.D., Patrick N.

2,717

0.01

0.0

Jun-13-2023


Graham, Shawn 

1,430

0.00

0.0

Jun-13-2023


Madhani CM, Bahadur 

750

0.00

0.0

Jun-13-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Graham, Shawn 
1,430
730

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
AXIMRIS XR (Future), Coreg CR (Future), Effexor XR, Focalin XR, Glucophage XR, IntelliFoam Technology, IntelliGITransporter Technology, IntelliMatrix Technology, IntelliOsmotics Technology, IntelliPaste Technology, Intellipellets Technology, IntelliShuttle Technology, Keppra XR, Lamictal XR (Future), Licensing of Focalin XR, Licensing of Lamictal XR, Licensing of Pristiq, Licensing of Seroquel XR, Lyrica, NanoFoam, nPODDDS Point of Divergence Drug Delivery System, Oleptro, Oxycodone ER (Future), OxyContin (Future), PODRAS Delivery Technology, Pristiq, Protonix, Ranexa, Regabatin XR (Future), Roxicodone (Future), Seroquel XR, SFT Technology, Venlafaxine ER


Upcoming Events
Date/Time
Type
Oct-13-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-06-2023
Oct-05-2023
Intellipharmaceutics International Inc. (TSX:IPCI)
SEC
6-K
473 KB
Oct-06-2023
Sep-14-2023
Intellipharmaceutics International Inc. (TSX:IPCI)
SEC
6-K
69 KB
Sep-29-2023
-
Intellipharmaceutics International Inc. (TSX:IPCI)
SEDAR
News Releases
102 KB
Sep-29-2023
-
Intellipharmaceutics International Inc. (TSX:IPCI)
SEDAR
Management Proxy Materials
88 KB
Sep-26-2023
May-31-2023
Intellipharmaceutics International Inc. (TSX:IPCI)
SEC
6-K
5 MB
Sep-26-2023
Feb-28-2023
Intellipharmaceutics International Inc. (TSX:IPCI)
SEC
6-K
4 MB
Jul-14-2023
-
Intellipharmaceutics International Inc. (TSX:IPCI)
SEDAR
News Releases
188 KB
Jul-14-2023
May-31-2023
Intellipharmaceutics International Inc. (TSX:IPCI)
SEDAR
Interim Financial Statements
258 KB
Jul-10-2023
-
Intellipharmaceutics International Inc. (TSX:IPCI)
SEDAR
Notice of the Meeting and Record Date
145 KB
Jun-15-2023
-
Intellipharmaceutics International Inc. (TSX:IPCI)
SEDAR
News Releases
189 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Akyempon, Christian  (Vice President of Commercial Operations)
Nov-26-2019
Common Shares
5,000
1,081
Open Market Acquisition
90.91
Exchange Announcement
Akyempon, Christian  (Vice President of Commercial Operations)
Sep-04-2018
Common Shares
250
-
Open Market Acquisition
83.33
Exchange Announcement
Akyempon, Christian  (Vice President of Commercial Operations)
Aug-29-2018
Common Shares
220
-
Open Market Acquisition
275.00
Exchange Announcement
Patient, Andrew P. (Former Consultant)
May-14-2018
Common Shares
2,722
16,012
Open Market Acquisition
37.41
Exchange Announcement
Patient, Andrew P. (Former Consultant)
May-11-2018
Common Shares
1,277
6,989
Open Market Acquisition
21.29
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Odidi, Isa 
Co-Founder, Chairman of the Board, CEO & Co-Chief Scientific Officer
416.798.3001x102
416 798 3007

Odidi, Amina 
President, COO, Co-Chief Scientific Officer, Acting CFO & Executive Director
(416) 798-3001
(416) 798-3007
aodidi@intellipharmaceutics.com
Betts, Norman M.
Independent Non-Executive Director
416 798 3001 
416 798 3007

Graham, Shawn 
Independent Non-Executive Director
416 798 3001 
416 798 3007

Madhani, Bahadur 
Independent Director
416 798 3001 
416 798 3007

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Odidi, Isa 
Co-Founder, Chairman of the Board, CEO & Co-Chief Scientific Officer
416.798.3001x102
416 798 3007

Odidi, Amina 
President, COO, Co-Chief Scientific Officer, Acting CFO & Executive Director
(416) 798-3001
(416) 798-3007
aodidi@intellipharmaceutics.com
Shaideen, Fazayill 
Controller
416 798 3001 
416 798 3007
-
Yat, Patrick N.
Vice-President of Chemistry & Analytical Services
416 798 3001 
416 798 3007

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
